share_log

Earnings Call Summary | Apyx Medical(APYX.US) Q4 2023 Earnings Conference

Futu News ·  Mar 22 01:31  · Conference Call

The following is a summary of the Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • Apyx Medical Corporation reported a 16% year-over-year increase in total revenue to $14.7 million in Q4 2023.

  • The company's gross profit for Q4 2023 stood at $8.9 million, at a 60.9% gross margin.

  • Advanced Energy equipment sales rose by 15% year-over-year to $12.1 million, contributing significantly to total revenue.

  • However, an increase in operating expenses of 4% led to a net loss increase of 59% to $9.6 million.

  • The company's gross margins declined slightly due to year-end inventory cleanup and changes in product and customer mix.

  • For 2024, Apyx expects total revenue to range between $49.7 million and $52.9 million with a projected gross margin of 61%.

Business Progress:

  • Apyx successfully launched the Renuvion Micro Handpiece, which received positive initial feedback.

  • Sales of handpieces showed strong growth within the U.S, up by over 35% year-over-year.

  • Internationally, Apyx reported a robust increase in generator sales by over 80% year-over-year.

  • In 2023, Apyx achieved its focus areas of securing additional clinical use indications, enhancing the portfolio, expanding clinical evidence, and managing expenses for profitability.

  • In 2024, the company aims to secure new customer adoption, particularly by simplifying the capital purchasing process.

  • The recently launched Micro Handpiece and Apyx One technology are key to the company's growth strategy, with emphasis on handpiece growth in 2024 and beyond.

  • The company continues international expansion efforts, including securing clearances in large cosmetic markets like Korea and China. It also aims to foster customer awareness through direct-to-consumer initiatives.

More details: Apyx Medical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment